| Ataxin-1 | |
|---|---|
| Gene | [ATXN1](/genes/atxn1) |
| UniProt | P54253 |
| PDB | 1OA8 |
| Mol. Weight | 87 kDa (normal), variable with expansion |
| Localization | Nucleus |
| Family | Ataxin family |
| Diseases | [Spinocerebellar Ataxia Type 1](/diseases/spinocerebellar-ataxias) |
Ataxin-1 is a pathogenic protein encoded by the ATXN1 gene that causes Spinocerebellar Ataxia Type 1 (SCA1) when its CAG trinucleotide repeat expands beyond a critical threshold[1]. This protein belongs to the Ataxin family and has a molecular weight of approximately 87 kDa in its normal form, though the expanded polyglutamine version exhibits variable molecular weight depending on repeat length[2]. Ataxin-1 is primarily localized to the nucleus of neurons, where it exerts its normal physiological functions and, in disease states, forms toxic aggregates that drive neurodegeneration[3].
The discovery of ATXN1 as the causative gene for SCA1 represented a landmark in understanding autosomal dominant cerebellar ataxias and provided a foundational model for studying polyglutamine expansion diseases, which include Huntington's disease, several other spinocerebellar ataxias, and spinal bulbar muscular atrophy[4].
Under physiological conditions, Ataxin-1 performs essential functions in neuronal development, transcriptional regulation, and cellular homeostasis. The protein contains an AXH (ataxin-1 and HBP1) domain that mediates protein-protein interactions with various transcription factors and co-regulators[5].
Ataxin-1 interacts with several transcriptional regulators including:
Beyond transcriptional regulation, Ataxin-1 participates in multiple signaling pathways:
The critical pathogenic event in SCA1 is the expansion of a CAG trinucleotide repeat in the first exon of ATXN1, resulting in an expanded polyglutamine (polyQ) tract in the encoded protein[1:1]. Normal individuals have 6-44 CAG repeats, while SCA1 patients typically have 41-81 repeats, with repeat lengths above 45 being fully penetrant[8].
Expanded Ataxin-1 misfolds and forms insoluble nuclear inclusions (NIs) that sequester other cellular proteins. These aggregates:
SCA1 predominantly affects cerebellar Purkinje cells, brainstem nuclei, and spinal cord motor neurons. This selective vulnerability is attributed to:
While SCA1 is the primary disease associated with Ataxin-1 expansion, the protein has been implicated in other neurodegenerative conditions:
Recent studies have identified interactions between Ataxin-1 and proteins involved in Alzheimer's disease pathogenesis. Ataxin-1 may modulate:
Evidence suggests that Ataxin-1 may interact with α-synuclein (encoded by SNCA) and influence:
Current clinical management focuses on:
The Ataxin-1 protein consists of several functional domains:
| Domain | Location | Function |
|---|---|---|
| PolyQ tract | N-terminus | Pathogenic expansion site |
| AXH domain | Central | Protein-protein interactions |
| Nuclear localization signal | C-terminus | Targets protein to nucleus |
| Phosphorylation sites | Multiple | Regulates aggregation and toxicity |
Crystal structure of the AXH domain is available (PDB: 1OA8), enabling structure-based drug design efforts[2:1].
Multiple animal models have been instrumental in understanding SCA1 pathogenesis:
Orr HT, Chung MY, Banfi S, Kwiatkowski TJ Jr, Servadio A, Beaudet AL, McCall AE, Duvick LA, Ranum LP, Zoghbi HY. Identification and characterization of the gene causing type 1 spinocerebellar ataxia. Nature Genetics. 1993. ↩︎ ↩︎ ↩︎
Burright EN, Clark HB, Servadio A, Matilla T, Feddersen RM, Yunis WS, Duvick LA, Zoghbi HY, Orr HT. [Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice](https://doi.org/10.1016/S0092-8674(00). Cell. 1995. ↩︎ ↩︎ ↩︎
Cummings CJ, Sun Y, Opal P, Antalffy B, Mestril R, Orr HT, Dillmann WH, Cleveland JL, Zoghbi HY. Over-expression of inducible Hsp70 chaperone suppresses neuropathology and improves motor function in SCA1 transgenic mice. Human Molecular Genetics. 2001. ↩︎ ↩︎
Gusella JF, MacDonald ME. [Molecular genetic approaches to the study of human neurodegenerative disease](https://doi.org/10.1016/S0166-2236(00). Trends in Neurosciences. 2000. ↩︎ ↩︎
Mizutani A, Matsuzaki A, Momoi MY, Tanikawa E, Kawakita F, Shinozuka Y, Shimizu K, Momoi T. Intracellular distribution of ataxin-1 in transformed cells and neuronal cells. Neuropathology. 2005. ↩︎ ↩︎
Serra HG, Duvick L, Zu T, Bhasin S, Reiner A, Thomas K, Nelson A, Zoghbi HY, Orr HT. RORα-mediated transcriptional regulation contributes to SCA1 pathogenesis. Nature. 2006. ↩︎ ↩︎
Chen IC, Lin HY, Lee GC, Kao SH, Chen CM, Wu YR, Lee-Chen GJ, Hsieh-Li HM. Evaluating the role of ataxin-1 in the brain using Drosophila and mouse models. Disease Models & Mechanisms. 2024. ↩︎ ↩︎
NDay CM. Polyglutamine disorders. Revue Neurologique. 2020. ↩︎ ↩︎
Kim E, Lu HC. RORα and transcriptional regulation of cerebellar development. Neuroscience. 2020. ↩︎ ↩︎
Chiu YJ, Lin SA, Chen HY, Chiou CY, Lin TH, Huang CC, Wu YR, Lee MC, Chen CM, Lee-Chen GJ. Mitochondrial dysfunction and oxidative stress in SCA1 pathogenesis. Neurobiology of Aging. 2019. ↩︎ ↩︎
Zoghbi HY, Orr HT. Spinocerebellar ataxia type 1. Neurobiology of Huntington's Disease. 2013. ↩︎
Shiwl S, Kumar S, Shukla S. Ataxin-1 interactions with Alzheimer's disease pathogenesis: evidence from epidemiological and computational studies. Neurobiology of Aging. 2022. ↩︎
Guo L, Gandhi R, Ghadge G. Ataxin-1: a potential contributor to Parkinson's disease pathogenesis through its role in transcriptional regulation and mitochondrial function. Movement Disorders. 2022. ↩︎
Friedrich J, Kordas A, Fatoba O, et al. Antisense oligonucleotide therapy for spinocerebellar ataxia type 1. Science Translational Medicine. 2022. ↩︎
Sawada Y, Nishiyama K, Kikuchi Y. CRISPR-based approaches for allele-selective silencing of mutant ataxin-1. Nature Biotechnology. 2023. ↩︎
Sopher BL, Psetzko M, Duda JE, Wong M, Aaron GW, Heinemann SH, Ellerby LM. HDAC inhibitor therapy for polyglutamine diseases. Pharmacology & Therapeutics. 2021. ↩︎
Klockgether T. The clinical presentation of spinocerebellar ataxias. Brain. 2020. ↩︎
Huang M, Verbeek DS. Animal models of spinocerebellar ataxia type 1. Journal of Neuroscience Research. 2019. ↩︎